Aromatase inhibitors, used in breast cancer treatment, have been linked to bone loss and an increased risk of fractures. Various strategies are being explored to manage this side effect, including the use of bisphosphonates and other treatments. The effectiveness of these approaches, as well as the challenges of maintaining healthy bones in patients taking aromatase inhibitors, are being studied and debated.